Literature DB >> 34391573

A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.

Jong-Hyuk Ahn1, Jung Hak Kwak1, Sang Gab Yoon2, Jin Wook Yi3, Hyeong Won Yu4, Hyungju Kwon5, Su-Jin Kim6, Kyu Eun Lee7.   

Abstract

BACKGROUND: The efficacy of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma remains controversial. We performed a randomized controlled trial to evaluate the efficacy and safety of prophylactic central compartment lymph node dissection in patients with papillary thyroid carcinoma.
METHODS: In this parallel-group randomized controlled trial, we assessed 101 patients aged 20 to 70 years with small/noninvasive papillary thyroid carcinoma and no clinical metastases or history of cervical surgery/radiation exposure. Randomization ran from April 2015 to November 2017. Data were collected between April 2015 and October 2020. Of the 101 enrolled patients, 50 underwent total thyroidectomy (TTx group) and 51 underwent total thyroidectomy as well as prophylactic central compartment lymph node dissection (TTx+pCND group). Surgical completeness, local recurrence, successful ablation, postoperative complication, and papillary thyroid carcinoma upstaging were compared between the 2 groups.
RESULTS: No patient showed structural recurrence after 46.6 ± 9.1 months of follow-up. Both groups had similar rates of surgical completeness and successful ablation. There was no difference in the incidence of complications. More patients were upstaged to pN1a in the TTx+pCND group compared to those in the TTx group (P < .05).
CONCLUSIONS: Prophylactic central compartment lymph node dissection detected more lymph node metastases but did not affect recurrence. The 2 groups showed similar outcomes with regard to surgical completeness, successful ablation, and complications. In conclusion, for small/noninvasive papillary thyroid carcinoma without clinical evidence of lymph node metastases, prophylactic central compartment lymph node dissection may not be required if total thyroidectomy is planned.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34391573     DOI: 10.1016/j.surg.2021.03.071

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Real-World Evidence on the Sensitivity of Preoperative Ultrasound in Evaluating Central Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Authors:  Fan Yao; Zhongyuan Yang; Yixuan Li; Weichao Chen; Tong Wu; Jin Peng; Zan Jiao; Ankui Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

Review 2.  A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess.

Authors:  David D Dolidze; Alexey V Shabunin; Robert B Mumladze; Arshak V Vardanyan; Serghei D Covantsev; Alexander M Shulutko; Vasiliy I Semikov; Khalid M Isaev; Airazat M Kazaryan
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

3.  Effect of a Polyglycolic Acid Mesh Sheet (Neoveil™) in Thyroid Cancer Surgery: A Prospective Randomized Controlled Trial.

Authors:  Seong Hoon Kim; Jong Hyuk Ahn; Hye Jeong Yoon; Jae Hwan Kim; Young Mi Hwang; Yun Suk Choi; Jin Wook Yi
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

4.  Ultrasonic Characteristics Improve Prediction of Central Lymph Node Metastasis in cN0 Unifocal Papillary Thyroid Cancer.

Authors:  Yongchen Liu; Jianhao Huang; Zhiyuan Zhang; Yijie Huang; Jialin Du; Sanming Wang; Zeyu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

5.  Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.

Authors:  Pu Wu; Jinyuan Shi; Zhiyuan Wang; Wei Sun; Hao Zhang
Journal:  Cancer Cell Int       Date:  2022-10-10       Impact factor: 6.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.